Global Hypercholesterolemia Drugs Market 2016-2020

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of  the report

• Market overview
• Top-vendor offerings
• Drug profiles

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights
• Clinical application
• Treatment guidelines
• Key buying criteria

PART 05: Hypercholesterolemia: An overview

• History of hypercholesterolemia
• Hypercholesterolemia management market dynamics
• Hypercholesterolemia prescription landscape
• Management of hypercholesterolemia
• Epidemiology
• Unmet medical needs and role of PCSK9 and CETP inhibitors

PART 06: Pipeline portfolio

• Information on pipeline candidates

PART 07: Market landscape

• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Segmentation  by type of disease

• FH
• Non-FH

PART 09: Market segmentation by MOA

• HMG-CoA reductase inhibitors
• Fibric acid derivatives
• Nicotinic acid
• Bile acid sequestrants
• Other

PART 10: Market segmentation by drug class

• Statins
• Non-statins

PART 11: Geographical segmentation

• Global hypercholesterolemia drugs market by geographical segmentation 2015-2020
• Hypercholesterolemia drugs market in Americas
• Hypercholesterolemia drugs market in EMEA
• Hypercholesterolemia drugs market in APAC

PART 12: Market drivers

• Increasing risk of CVDs
• Rising prevalence of chronic diseases
• Promising pipeline of drugs
• Change in ATP guidelines for management of hypercholesterolemia
• Growing older population

PART 13: Impact of drivers

PART 14: Market challenges

• Loss of patent exclusivity of branded therapies
• Drawbacks associated with current therapies
• High cost of therapy
• Stringent regulatory guidelines
• Lack of proper diagnosis

PART 15: Impact of drivers and challenges

PART 16: Market trends

• Expected entry of cost-effective OTC versions
• Increasing use of statins
• Increased use of combination therapies
• Consideration of lifestyle management in ATP guidelines

PART 17: Vendor landscape

• Competitive scenario
• Market share analysis 2015

PART 18: Key vendor analysis

• AbbVie
• Aegerion Pharmaceuticals
• AstraZeneca
• Merck
• Pfizer
• Sanofi
• Other prominent vendors

PART 19: Appendix

• List of abbreviations

PART 20: Explore Technavio